We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
Cap. Flow
+$166M
Cap. Flow %
7.61%
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$46.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$38.5M
3
ZLAB icon
Zai Lab
ZLAB
+$38.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.8M
5
EDIT icon
Editas Medicine
EDIT
+$26M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$48.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.5M
3
SRRK icon
Scholar Rock
SRRK
+$20M
4
DNLI icon
Denali Therapeutics
DNLI
+$17.3M
5
CYTK icon
Cytokinetics
CYTK
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 86.67%
2 Miscellaneous 11.02%
3 Financials 2.15%
4 Real Estate 0.05%
5 Communication Services 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
326
CALL
Replimune Group
REPL
$1.46B
– –
-100,000
Closed -$765K
RGNX icon
327
Regenxbio
RGNX
$638M
– –
-44,416
Closed -$372K
SDGR icon
328
Schrodinger
SDGR
$1.47B
– –
-101,500
Closed -$1.15M
SGRY icon
329
Surgery Partners
SGRY
$1.79B
– –
-20,000
Closed -$238K
SLNO
330
DELISTED
Soleno Therapeutics
SLNO
– –
-46,830
Closed -$1.57M
SNDX icon
331
Syndax Pharmaceuticals
SNDX
$1.74B
– –
-17,500
Closed -$409K
SRRK icon
332
Scholar Rock
SRRK
$7.04B
– –
-407,273
Closed -$20M
SRZN icon
333
Surrozen
SRZN
$264M
– –
-12,000
Closed -$350K
SXT icon
334
Sensient Technologies
SXT
$5.75B
– –
-15,000
Closed -$1.3M
TERN
335
CALL
DELISTED
Terns Pharmaceuticals
TERN
– –
-200,000
Closed -$10.5M
TERN
336
DELISTED
Terns Pharmaceuticals
TERN
– –
-914,699
Closed -$48.2M
TFX icon
337
Teleflex
TFX
$5.92B
– –
-21,186
Closed -$2.53M
STLN
338
Starling Oncology
STLN
$629M
– –
-50,000
Closed -$154K
UNH icon
339
UnitedHealth
UNH
$353B
– –
-5,501
Closed -$1.49M
VRDN icon
340
Viridian Therapeutics
VRDN
$2.61B
– –
-304,422
Closed -$5.95M
VRTX icon
341
Vertex Pharmaceuticals
VRTX
$137B
– –
-15,075
Closed -$6.73M
AVBP icon
342
ArriVent BioPharma
AVBP
$1.49B
– –
-141,814
Closed -$3.27M
GUTS icon
343
CALL
Fractyl Health
GUTS
$105M
– –
-1,428,571
Closed -$654K
KYTX icon
344
Kyverna Therapeutics
KYTX
$518M
– –
-22,428
Closed -$194K
QTTB icon
345
Q32 Bio
QTTB
$447M
– –
-35,000
Closed -$225K
RBRK icon
346
Rubrik
RBRK
$19.2B
– –
-4,900
Closed -$240K
BIOA
347
BioAge Labs
BIOA
$443M
– –
-135,560
Closed -$2.37M
UPB
348
Upstream Bio Inc
UPB
$366M
– –
-35,000
Closed -$315K
BSAAU
349
BEST SPAC I Acquisition Corp Unit
BSAAU
– –
-100,000
Closed -$1.04M
10 11 12 13
14

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.

  • ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
  • ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
  • ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
  • ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
  • ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
  • ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
  • ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.